

# Journal of Visualized Experiments

## Exogenous administration of microsomes-associated alpha-synuclein aggregates to primary neurons as a powerful cell model of fibrils formation.

--Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE57884R2
<b>Full Title:</b>	Exogenous administration of microsomes-associated alpha-synuclein aggregates to primary neurons as a powerful cell model of fibrils formation.
<b>Keywords:</b>	Alpha-synuclein; aggregates; microsomes; primary neurons; Parkinson's disease; cell model
<b>Corresponding Author:</b>	Emanuela Colla Scuola Normale Superiore Pisa, ITALY
<b>Corresponding Author's Institution:</b>	Scuola Normale Superiore
<b>Corresponding Author E-Mail:</b>	emanuela.colla@sns.it
<b>First Author:</b>	Giulia Panattoni
<b>Other Authors:</b>	Giulia Panattoni
<b>Author Comments:</b>	
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter.	



SCUOLA  
NORMALE  
SUPERIORE

**Emanuela Colla, PhD**

Ricercatore TD

Laboratorio di Biologia (BIOSNS)

Scuola Normale Superiore

Piazza dei Cavalieri 7

Pisa 56124

P: 050-3153198

Fax: +390503153220

Email: emanuela.colla@sns.it

Pisa, 5<sup>th</sup> March 2018

Dear Dr Bajaj,

please find attached my revised manuscript (JoVE57884) of title: Exogenous administration of microsomes-associated alpha-synuclein aggregates to primary neurons as a powerful cell model of fibrils formation. In this revision we think we addressed all the editorial comments as stated in our response letter.

Thank you for your attention.

Best regards,

Emanuela Colla, PhD

---

Piazza dei Cavalieri, 7

56126 Pisa-Italy

tel: +39 050 509111

fax: +39 050 563513

**TITLE:**

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons as a Powerful Cell Model of Fibrils Formation

**AUTHORS AND AFFILIATIONS:**

Giulia Panattoni<sup>1,2</sup>, Emanuela Colla<sup>1</sup>

<sup>1</sup>Bio@SNS Laboratory, Scuola Normale Superiore, Pisa, Italy,

<sup>2</sup>International School for Advanced Studies (SISSA/ISAS), Trieste, Italy.

**CORRESPONDING AUTHOR:**

Emanuela Colla (emanuela.colla@sns.it)

Tel: +393299865040

**EMAIL ADDRESSES OF CO-AUTHORS:**

Giulia Panattoni (gpanatto@sissa.it)

**KEYWORDS:**

Alpha-synuclein; aggregates; microsomes; primary neurons; Parkinson's disease; cell model.

**SUMMARY:**

The goal of this protocol is to provide a cell-based system that replicates the formation of alpha-synuclein aggregates *in vivo*. Intracellular alpha-synuclein inclusions are seeded in primary neurons by the internalization and propagation of exogenous administered native microsomes-associated alpha-synuclein aggregates isolated from diseased alpha-synuclein transgenic mice.

**ABSTRACT:**

For years, the inability of replicating formation of insoluble alpha-synuclein ( $\alpha$ S) inclusions in cell cultures has been a great limitation in the study of  $\alpha$ S aggregation in Parkinson's Disease (PD). Recently, the development of new animal models through the exogenous inoculation of brain extracts from diseased  $\alpha$ S transgenic mice or PD patients has given new hopes to the possibility of creating more adequate cell models of  $\alpha$ S aggregation. Unfortunately, when it comes to cells in cultures, administration of raw brain extracts has not proven as successful as in mice and the source of choice of exogenous aggregates is still *in vitro* preformed  $\alpha$ S fibrils.

We have developed a method to induce the formation of intracellular  $\alpha$ S inclusions in primary neurons through the exogenous administration of native microsomes-associated  $\alpha$ S aggregates, a highly toxic  $\alpha$ S species isolated from diseased areas of transgenic mice. This fraction of  $\alpha$ S aggregates that is associated with the microsomes vesicles, is efficiently internalized and induces the formation of intracellular inclusions positive for aggregated and phosphorylated  $\alpha$ S. Compared to *in vitro*-preformed fibrils which are made from recombinant  $\alpha$ S, our method is faster and guarantees that the pathogenic seeding is made with authentic  $\alpha$ S aggregates extracted from diseased animal models of PD, mimicking more closely the type of inclusions

obtained *in vivo*. As a result, availability of tissues rich in  $\alpha$ S inclusions is mandatory.

We believe that this method will provide a versatile cell-based model to study the microscopic aspects of  $\alpha$ S aggregation and the related cellular pathophysiology *in vivo* and will be a starting point for the creation of more accurate and sophisticated cell paradigm of PD.

## INTRODUCTION:

Accumulation of alpha-synuclein ( $\alpha$ S) proteinaceous inclusions is a prominent and important feature of Parkinson's Disease (PD) and alpha-synucleinopathies<sup>1</sup>. Unfortunately, while animal models are able to provide a sufficient cellular and biochemical environment to induce the aggregation steps necessary for the formation of protein fibrils<sup>2</sup>, replicating formation of complex Lewy Body (LB)-like aggregates in cell cultures is difficult and challenging.

Here we describe a method to induce the formation of  $\alpha$ S inclusions, similar to protein aggregates obtained in animal models and PD patients, in cultured cells, using brain isolated mouse primary neurons. Our protocol is based on the exogenous administration of microsomes-associated  $\alpha$ S aggregates isolated from  $\alpha$ S symptomatic transgenic (Tg) mice to mouse hippocampal or cortical primary neurons. This method takes advantage of the spreading and propagation ability of  $\alpha$ S toxic species which, once added to the culture medium, are able to become internalized and induce the formation of mature  $\alpha$ S-positive aggregates.<sup>3-8</sup>

Originally, standard methods to obtain formation of  $\alpha$ S fibrils in cell cultures were based on the overexpression of the corresponding  $\alpha$ S cDNA through the regular transfection protocols or viral-mediated infection<sup>9</sup>. While in the first case obtaining LB-like  $\alpha$ S aggregates were fortuitous, showed low efficiency, and depended on the cell type, the second protocol led to the formation of insoluble fibrils, including high molecular weight (HMW) species in 24 - 48 h from infection<sup>10</sup>. In these methods, the formation of aggregates was probably due to an excessive and unbalanced in  $\alpha$ S protein amount that becomes insoluble rather than a pathological conversion of the  $\alpha$ S conformation that dictates aggregation. Instead, the technique that we are presenting here does not alter the  $\alpha$ S expression level but induces widespread protein aggregation due to the internalization of exogenous fibrils. Moreover, the formation of  $\alpha$ S aggregates through the administration of exogenous fibrils is a lengthy process that requires days or weeks to become exhaustive allowing us to study early and intermediate stages of  $\alpha$ S inclusions formation in a time-lapse fashion and to correlate it with the cellular biochemical changes. Thus, our method is a valuable application to create cellular models of  $\alpha$ S aggregation that are helpful to study  $\alpha$ S fibril formation microscopically in relation to cellular pathophysiology.

In addition although administration of raw brain extracts from diseased  $\alpha$ S Transgenic (Tg) mice<sup>11,12</sup> or human PD brains<sup>6,13</sup> is able to induce  $\alpha$ S deposition in Tg or wild-type (WT) animals, application of the same procedure to cell cultures has not proven to be as successful, possibly because of the low amount of aggregates in the samples used and the lack of a standard procedure to isolate native  $\alpha$ S toxic species<sup>14</sup>. Because of this, *in vitro* preformed fibrils (PFFs) of  $\alpha$ S have been the aggregates source of choice until now for the induction of  $\alpha$ S inclusions in cells

and animal models<sup>3,4,6,7,15,16</sup>. With our protocol, however, we show that microsomes-associated  $\alpha$ S aggregated species isolated from  $\alpha$ S Tg mice can efficiently induce accumulation of intracellular LB-like  $\alpha$ S inclusions in primary neurons.

In our lab, microsomes-associated  $\alpha$ S aggregated species are isolated from the spinal cord (SpC) tissue of the diseased Tg mice expressing human A53T  $\alpha$ S gene under the control of the mouse prion protein (PrP) promoter [Prp Human A53T  $\alpha$ S Tg mice, Line G2-3<sup>17</sup>]. These mice show an age-dependent neurodegenerative phenotype that includes robust motor dysfunction and formation of inclusions in the central nervous system made of phosphorylated, ubiquitinated and insoluble  $\alpha$ S, starting after 9 months of age. Once motor dysfunction appears, the phenotype rapidly evolves into paralysis, starting from posterior limbs, that leads to the death in 2-3 weeks. Accumulation of  $\alpha$ S aggregates parallels disease manifestation. Mice sacrificed at the onset of the motor dysfunction show a robust degree of  $\alpha$ S aggregation in the SpC, brain stem and cerebellum. There is no need to wait until paralysis sets to sacrifice the mouse. Presymptomatic mice are taken at 9 months-old animals that do not display motor dysfunction.

#### **PROTOCOL:**

The use of WT and Tg animals was approved and complied in full by the national and international laws for laboratory animal welfare and experimentation (EEC council directive 86/609, 12 December 1987 and Directive 2010/63/EU, 22 September 2010). All the protocols described in this paper follow the animal care guidelines of our institution.

#### **1. Isolation of Microsomes-associated $\alpha$ S Aggregates from Diseased A53T $\alpha$ S Tg Mice**

1.1. Prepare the homogenization buffer which is composed of 250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl<sub>2</sub>, 2 mM EDTA and 1x phosphatase/protease-inhibitors. Keep the buffer on ice.

1.2. Homogenize the fresh or frozen tissue in a 1:10 (w/v) volume of ice-cold homogenization buffer using a Teflon pestle homogenizer, with 10-15 strokes.

1.3. Transfer initial homogenate (1-2 mL) to a microcentrifuge tube and centrifuge at 1,000  $\times g$  for 10 min at 4 °C using a refrigerated centrifuge in order to remove nuclei and unbroken cells in the resulting pellet (P1). Discard P1.

1.4. Transfer the supernatant (S1) to a clean microcentrifuge tube and centrifuge S1 at 10,000  $\times g$  for 20 min at 4 °C using a refrigerated centrifuge in order to obtain the second supernatant (S10) and the pellet (P10).

Note: P10 is a crude membrane pellet that contains mitochondria and synaptosomes. Discard P10.

1.5. Transfer the supernatant (S10) to a polycarbonate bottle (>1 mL) and centrifuge S10 at

100,000  $\times g$ , for 1 h at 4 °C using an ultracentrifuge and a fixed angle rotor (90 Ti).

Note: The supernatant is the pure cytosol fraction while the pellet, P100, contains microsomes-associated  $\alpha S$  aggregates.

1.6. Resuspend the P100 pellet with 200  $\mu L$  of the homogenization buffer. Transfer P100 to a clean microcentrifuge tube and centrifuge at 10,000  $\times g$  for 20 min at 4 °C in a refrigerated centrifuge.

1.7. Discard the supernatant and resuspend P100 with 100  $\mu L$  of homogenization buffer.

Note: This fraction is the microsomes-associated  $\alpha S$  aggregates.

1.8. Sonicate samples for 2 s on ice [set output power 1 watt (RMS)]. Store samples at -80 °C.

1.9. The day after, determine the protein amount using BCA analysis.

## 2. Western Blot

Note: Biochemical characterization of the microsomes-associated  $\alpha S$  aggregates is evaluated by Western Blot.

2.1. Cast a gradient 4-20% Tris-glycine polyacrylamide gel on a vertical electrophoresis apparatus.

2.2. Load 1  $\mu g$  of microsomes-associated  $\alpha S$  fractions, dissolved in the denaturing sample buffer.

2.3. In a different well, load 5  $\mu L$  of protein standard marker.

2.4. Run the gel at 100 V in a Tris/glycine/SDS running buffer until protein marker reaches the end of the gel.

2.5. Transfer proteins to a nitrocellulose membrane using a basic carbonate buffer (10 mM  $NaCO_3$ , 3 mM  $NaHCO_3$ , 20% Methanol) O/N at 4 °C, at 200 mA, constant.

2.6. Block the membrane with PBS-nonionic surfactant 0.05% (PBS-T) with 5% non-fat dry milk on an orbital shaker for 30 min at RT.

2.7. Briefly, rinse the membrane with PBS-T.

2.8. Incubate the membrane with Syn-1 (1:5,000) or pSer129- $\alpha S$  antibody (1:5, 000) in 2.5% non-fat dry milk in PBS-T, O/N at 4 °C on an orbital shaker.

2.9. Wash the membrane for 10 min at RT with PBS-T on an orbital shaker.

2.10. Incubate the membrane with anti-mouse or anti-rabbit HRP-conjugated secondary antibody (1:3,000) in 2.5% non-fat dry milk in PBS-T for 1 h at RT.

2.11. Wash the membrane for 10 min at RT with PBS-T on an orbital shaker. Repeat 3x.

2.12. Obtain the signal through the regular chemiluminescence kits.

### 3. Primary Neuronal Cultures

Note: Primary neuronal cultures were prepared from the WT newborn (P0) mouse hippocampus or cortex (Line C57BL/6). The entire procedure, minus the centrifugation steps, is carried out under a cell culture hood, in sterile conditions.

3.1. Treat coverslips (18 mm  $\varnothing$ ) with 65% nitric acid solution for at least 12 h at RT.

3.2. Remove the nitric acid. Rinse coverslips twice with PBS 10x and several times with distilled water.

3.3. Insert coverslips in 24-well dishes and coat them with poly-D-lysine (0.1 mg/mL in sterile distilled water or PBS 1x) for 1 h at 37 °C.

3.4. Remove poly-D-lysine and wash the coverslips three times with distilled water. Store them at 4 °C until needed.

3.5. Euthanize the mouse pups by decapitation and separate the heads from the bodies. Place the heads on dishes and gently dissect the skin.

3.6. By using fine scissors, open the skull by making an incision at the bases of the brains. Separate the two halves of the skulls and remove them carefully.

3.7. By using forceps, pinch off the brains from the bases and isolate the cortex and the hippocampus. Transfer them into two separate dishes containing Hank's Balanced Salt Solution (HBSS) medium containing 1% penicillin/streptomycin.

3.8. Repeat steps 3.6 and 3.7 for each animal. Be aware that the entire process should not take more than 30-45 min.

3.9. Mince the collected tissues and transfer them into two 50 mL conical tubes (one for hippocampus and one for cortex) with 10 mL of HBSS medium containing Trypsin 0.1%. Incubate in the water bath for 7 min at 37 °C.

Note: No agitation is required.

3.10. Add 1 mL of DMEM containing 10% fetal bovine serum (FBS) and 10 µg/mL DNase to the homogenate to block trypsin activity.

3.11. Centrifuge the resulting dissociated tissue at  $200 \times g$  for 5 min at RT on a centrifuge and remove the supernatant.

Note: The pellet represents the cells dissected from the tissue.

3.12. Resuspend the cells in the plating medium, containing 2% B27, 2 mM glutamine, 6 mg/mL glucose, 10% FBS, 12.5 µM glutamate and 10 µg/mL gentamicin.

3.13. Plate dissociated neurons on poly-D-Lysine coverslips in 24 well plates according to the ratio: 1 cortex/12 wells and 1 hippocampus/6 wells, resulting in approximately 150,000/200,000 cells per well. Maintain the cells in the incubator at 37 °C.

3.14. The day after (day *in vitro*, DIV 1), replace the plating medium with the medium containing 2% B27, 10 µg/mL gentamicin and 2 mM glutamine.

3.15. At DIV 2, remove 1/3 of medium and add 1/3 of the fresh medium containing 2.5 µM cytosine arabinoside for 48 h to reduce the glial contamination.

3.16. Maintain neurons at 37 °C and replace half of the medium every three days.

#### 4. Neurons Treatment

Note: The treatment has been performed at DIV 7. All the steps are carried on under a cell culture hood in sterile conditions. An example of cortical neuronal culture density at DIV 7 is illustrated in **Figure 1**.

4.1 Pool microsomes-associated αS aggregates obtained from the spinal cord of three different diseased Tg mice in order to have a 1 µg/µL solution, using the original homogenization buffer for the dilution.

4.2 Remove 1/3 of the medium and replace it gently with the fresh medium containing 2% B27, 1x gentamicin and 2 mM glutamine.

4.3 Add 1 µg of pooled microsomes-associated αS aggregates to the cell medium. Return neurons in the incubator at 37 °C.

4.4 Every 3 days for 1 week, add 1/3 of fresh medium. Do not replace the medium. Just add it.

4.5 After 1 week of treatment, remove 1/3 of the medium and replace it gently with the fresh medium containing 2% B27, 10 µg/mL gentamicin and 2 mM glutamine. Repeat every 3 days.



4.6 Fix neurons after 2 weeks of treatment (DIV 21).

## 5. Immunofluorescence

5.1. Fix neurons with 2% paraformaldehyde in PBS 1x and 5% sucrose solution for 15 min at RT without shaking, under a chemical fume hood.

5.2. Remove the fixing solution. Briefly, wash with PBS 1x, 3 times.

Note: Perform all the washing steps gently because primary neurons do not stick firmly to poly-lysine coverslips.

5.3. Permeabilize neurons with 0.3% of nonionic surfactant in PBS 1x for 5 min at RT.

5.4. Briefly, wash with PBS 1x, 3 times.

5.5. Incubate neurons with 3% FBS in PBS 1x for 30 min at RT, to block unspecific binding sites, on an orbital shaker.

5.6. Incubate neurons with appropriate primary antibody dissolved in 3% FBS in PBS 1x, O/N at 4 °C on an orbital shaker.

Note: syn303 (1:1,000), mouse  $\alpha$ S (1:200), pser129- $\alpha$ S (1:1,000) and Tau (1:10,000) antibodies were used.

5.7. Remove the antibody solution and wash, briefly, with PBS 1x, 3 times.

5.8. Incubate neurons with appropriate fluorescent secondary antibody dissolved in 3% FBS in PBS, for 1 h at RT in the dark on an orbital shaker.

5.9. Remove the antibody solution and wash, briefly, with PBS 1x, 3 times.

5.10. Stain neurons with DAPI solution (0.1  $\mu$ g/mL in PBS 1x) for 15 min at RT in the dark on an orbital shaker.

5.11. Remove the antibody solution and wash, briefly, with PBS 1x, 3 times.

5.12. Mount coverslips on a slide using antifade mounting medium.

## REPRESENTATIVE RESULTS:

Following the protocol described above and summarized in **Figure 2**, we purified microsomes-associated  $\alpha$ S aggregates from three diseased A53T  $\alpha$ S Tg mice (**Figure 3**). Microsomes are crude membrane pellet fractions that contain the endoplasmic reticulum, Golgi, and small synaptic vesicles. The degree of purity of the microsomal pellet compared to other fractions was

previously evaluated using specific organelle markers<sup>18</sup>.

Once isolated, biochemical characterization of  $\alpha$ S aggregates is assessed through denaturing SDS-Page, followed by incubation with Syn-1 or phosphorylated  $\alpha$ S at Serine 129 (pSer129- $\alpha$ S) antibody. Compared to presymptomatic (PreS) and age-matched non-Tg (nTg) mice, microsomes isolated from sick mice co-precipitate with  $\alpha$ S aggregates. Microsomes-associated  $\alpha$ S species show the typical features of  $\alpha$ S aggregates, such as accumulation of HMW detergent-resistant species, phosphorylation at serine 129<sup>19</sup> and C-and N-terminal truncated fragments (for a full characterization of microsomes-associated  $\alpha$ S aggregates see reference<sup>18,20,21</sup>). These are fundamental requirements since monomeric  $\alpha$ S does not get efficiently internalized and does not induce  $\alpha$ S deposition<sup>7,15,22</sup>. It is important not to use any detergent (ionic or non-ionic) to resuspend P100 pellets since it can be harmful to cells. Also, in order to avoid sample variability, microsomes-associated  $\alpha$ S aggregates from three different diseased mice will be pooled for neuronal treatment.

Administration of 1  $\mu$ g of pooled microsomes-associated  $\alpha$ S aggregates from diseased A53T mice to the culture medium of cortical or hippocampal neurons induces a time-dependent formation of  $\alpha$ S inclusions, positive for aggregates-specific  $\alpha$ S antibodies such as Syn303 (**Figure 4, 5**) or pser129- $\alpha$ S (**Figure 5**). After two days (2d) of treatment these aggregates appear as small, scattered puncta that will become more abundant at later time points. After two weeks,  $\alpha$ S inclusions resemble long and mature beads-like structures, heavily spread throughout the neuronal cultures, following a neurite pattern and partially co-localizing with presynaptic and neurites markers (**Figure 5**). Occasionally, newly formed  $\alpha$ S inclusions can be seen to co-localize and stain the cell soma or cover the entire process, resembling necrotic neurites.

Although microsomes-associated  $\alpha$ S aggregates fractions can efficiently spread in neuronal cultures, their amount has to be finely tuned to the number of neurons plated (**Figure 1**). In fact, exceeding the recommended ratio,  $\mu$ g of microsomes-associated aggregates: number of neurons, will induce premature cell death within a few days (**Figure 6**), while an insufficient amount of microsomes-associated  $\alpha$ S aggregates will lead to a scarce and reduced number of inclusions after two weeks of treatment, similar to what was obtained at earlier time points (**Figure 4A**).

#### FIGURE AND TABLE LEGENDS:

**Figure 1. Cortical neuronal cultures.** Representative image showing density at DIV 7 of cortical neuronal cultures. Images were taken with an inverted light microscope, 10X objective. Scale bar = 100  $\mu$ m.

**Figure 2. Isolation of microsomes-associated  $\alpha$ S aggregates from mouse SpC.** Flowchart of the purification protocol of microsomes-associated  $\alpha$ S aggregates from SpC of diseased mice.

**Figure 3. Isolation of microsomes fractions from diseased, presymptomatic A53T  $\alpha$ S Tg and nTg mice.** Western blot analysis showing purified microsomes-associated  $\alpha$ S aggregates isolated

from three diseased (Sick), presymptomatic (PreS) and aged-matched nTg mice. Diseased mice are A53T  $\alpha$ S Tg mice that show the motor and neurological dysfunction, including the accumulation of  $\alpha$ S inclusions, while presymptomatic animals are healthy A53T  $\alpha$ S Tgs of 9 months of age that do not show yet any  $\alpha$ S pathology related phenotype. nTg mice are littermates of diseased mice which do not carry the  $\alpha$ S transgene and therefore do not develop  $\alpha$ S induced pathology. 1  $\mu$ g of each purified fractions were run on a denaturing SDS-Page, transferred on a nitrocellulose membrane and blotted with Syn-1 or pSer129- $\alpha$ S antibody. Only microsomes fractions isolated from sick mice contained HMW detergent-resistant  $\alpha$ S aggregates that were phosphorylated at serine 129 and showed C-and N-terminal truncation. This figure has been adapted from Colla *et al.*<sup>18</sup>.

**Figure 4. Time-dependent induction of  $\alpha$ S deposition after administration of microsomes-associated  $\alpha$ S aggregates.** (A) Immunofluorescence of primary hippocampal neurons treated with 1  $\mu$ g of microsomes-associated  $\alpha$ S aggregates fractions pooled from three different diseased mice. Neurons were fixed at 2 days (2d), 1 week (1w) or 2 weeks (2w) of treatment and immunostained with syn303 (S303, 1:1000), an antibody specific for oxidized and aggregated  $\alpha$ S. Cells were counterstained with DAPI. Confocal images were taken using a laser scanning confocal microscope, 63X objective. Scale bar = 50  $\mu$ m. (B) Quantitative analysis of total fluorescence, after background subtraction, was done using the particles count plugin of the Image J software. Values were normalized for the number of nuclei per field (DAPI count) and expressed as the percentage of the S303 fluorescence signal at 2D. Values are given as the mean  $\pm$  SD (n =5). \*\*p < 0.001, \*\*\*\*p < 0.00001, One-way ANOVA, followed by Fisher's LSD post-hoc test.

**Figure 5. Intracellular  $\alpha$ S inclusions colocalize with cortical neurites network.** Representative confocal images of cortical neurons treated with microsomes-associated  $\alpha$ S aggregates obtained from diseased Tg mice. After 2 weeks of treatment neurons were fixed and double stained with aggregates-specific antibodies [S303 (A, B) or pser129- $\alpha$ S, 1:1,000 (C)] and neurite markers [mouse  $\alpha$ S, 1:200 (A,B) or Tau, 1:10,000 (C)]. Co-labelling of the fluorescent signals demonstrated partial co-localization of newly formed  $\alpha$ S bead-like structures with the neurites network. Occasionally  $\alpha$ S inclusions accumulate within the neuronal soma (A, B, arrowheads). Stacked images were acquired with a laser scanning confocal microscope, 63x objective. Scale bar = 50  $\mu$ m. This figure has been modified from Colla *et al.*<sup>20</sup>.

**Figure 6. Addition of suboptimal amount of microsomes-associated  $\alpha$ S aggregates is toxic to neurons.** DAPI staining of neurons treated with increasing concentration of microsomes-associated  $\alpha$ S aggregates leads to cell death. (A) Cortical neurons were treated with 1, 2  $\mu$ g of microsomes-associated  $\alpha$ S aggregates extracted from diseased mice or only buffer that does not contain aggregates (B) and stained with DAPI. Fluorescent images were acquired with an epifluorescence microscope using a 20X objective. Scale bar =100  $\mu$ m. (B) DAPI-positive cells were counted using the Image J software. The graph shows a reduction in the number of nuclei with increasing concentration of microsomes-associated  $\alpha$ S aggregates added to the neuronal media. Values are expressed as % of b and are given as the mean  $\pm$  SD (n =5), \*\*\*p < 0.0001, One-way ANOVA, followed by Fisher's LSD post-hoc test.

## DISCUSSION:

We described a method to obtain formation of  $\alpha$ S inclusions in brain-derived primary neuronal cultures from WT mice, through the addition of purified microsomes-associated  $\alpha$ S aggregates isolated from  $\alpha$ S Tg animal models.

Critical steps of this protocol are the following: the ratio of  $\mu$ g of microsomes-associated  $\alpha$ S aggregates/neurons and the source of  $\alpha$ S aggregates. As shown in the results session, it is crucial to optimize the ratio of  $\mu$ g of microsomes-associated  $\alpha$ S aggregates/number of neurons since working in suboptimal conditions can lead to the premature cell death or too scarce intracellular aggregation (see the Representative Results section). Because of this, it is very important to assess the density of the neuronal culture at DIV 7 (shown in **Figure 1**) before starting the treatment. Additionally,  $\alpha$ S aggregates have to be purified from diseased  $\alpha$ S Tg mice, i.e. from animal models that accumulate LB-like inclusions characterized by phosphorylated and detergent insoluble  $\alpha$ S HMW fibrils.

Possible modifications to this protocol regard the tissue, frozen or fresh, from which microsomes can be isolated and the starting amount. While we used SpC of Tg mice because of the high content of  $\alpha$ S insoluble aggregates, the protocol is suitable to isolate microsomes-associated aggregates from any tissues, provided that the area has a high content in  $\alpha$ S aggregates. Frozen samples can also be used since freezing does not affect the purification steps of microsomes-associated aggregates or the aggregates *per se*. While the recommended starting weight for tissues is about 100-150 mg, this protocol is suitable for obtaining microsomes from as low as 50 mg of raw material (no maximum weight limit). In the case of the amount lower than 100 mg, however, the appropriate homogenization ratio will be 1:20 (w/v) in order to have at least 1 mL of supernatant S10 to load on the polycarbonate bottle for the ultracentrifuge precipitation. In fact, loading volumes smaller than 1 mL may result in the collapse of the tube and sample loss. Increasing the homogenization volume will lead to a more diluted supernatant but the concentration of the microsomal pellet will remain unaffected.

A limitation of this protocol concerns the inefficient cross-seeding in the formation of  $\alpha$ S inclusions that have been recently reported in the case administration of  $\alpha$ S PFFs of human origin to murine neuronal cultures as opposed to mouse  $\alpha$ S PFFs<sup>24</sup>. Since increasing the amount of exogenous  $\alpha$ S fibrils given to murine cultures can bypass this issue, we recommend to finely tune the amount of microsomes-associated aggregates in the case of administration of fibrils obtained from other  $\alpha$ S variants or from different species to mouse neuronal cultures than what we described.

Exogenous  $\alpha$ S aggregates added to the culture media can be from different sources. *In vitro*  $\alpha$ S PFFs have been previously used as seeding template of intracellular  $\alpha$ S aggregates in cell cultures, primary neurons, and animal models<sup>3,7,8,15</sup>. Compared to our method where microsomes-associated  $\alpha$ S aggregates can be isolated in few hours, the formation of PFFs is lengthy and laborious, requiring multiple steps of purifications, followed by additional assays to check  $\alpha$ S

aggregates conformations<sup>25</sup>. In addition, PFFs being obtained from bacterial-expressed human or mouse  $\alpha$ S, *i.e.* lacking posttranslational modifications typical of eukaryotes, can present different conformations, with selective seeding and pathogenic properties, according to the nucleation protocols followed (*i.e.* ribbons vs fibrils)<sup>5,8</sup> leading to different results and conclusions. Instead, single administration of *in vivo* purified  $\alpha$ S aggregates guarantees the transmission of more authentic pathogenic templates, mimicking closely the process of formation of  $\alpha$ S inclusions in animal models and PD patients.

As a future application of this technique, we believe that this protocol can be successfully used to isolate  $\alpha$ S pathogenic seeds from the brain of PD patients or other  $\alpha$ S Tg animal models, provided that diseased area from which microsomes are isolated are rich in  $\alpha$ S inclusions.

To our knowledge, this is the first method that allows the purification of native toxic species of  $\alpha$ S from *in vivo* PD models to be used as seeding template for obtaining formation of  $\alpha$ S inclusions in primary neurons.

We believe that this method is extremely versatile and can provide an exceptional cell-based model to study the different aspects of  $\alpha$ S aggregation and its influence on the cell pathophysiology. Because the formation of  $\alpha$ S inclusions represent a complex process that has been difficult to replicate in cultured cells, we are hopeful that this model will provide great insights in acute pathogenic mechanisms, hard to identify in chronic and more elaborate systems such as are animal models.

#### ACKNOWLEDGMENTS:

This work has been supported by the Italian Ministry of University and Research (MIUR) through the Career Reintegration grant scheme (RLM Program for Young Researcher) and from Scuola Normale Superiore. We thank Prof Michael Lee from University of Minnesota, USA, for providing the Prp Human A53T  $\alpha$ S Tg mice, from which aggregates are isolated.

Dr. Fabiana Miraglia and Dr. Lucia Rota will appear in the video.

#### DISCLOSURES:

The authors have nothing to disclose.

#### REFERENCES:

1. Goedert, M., Spillantini, M. G., Del Tredici, K. & Braak, H. 100 years of Lewy pathology. *Nat. Rev. Neurol.* **9**, 13–24, doi: 10.1038/nrneurol.2012.242 (2012).
2. Visanji, N. P. *et al.*  $\alpha$ -Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. *Trends Neurosci.* **39**, 750–762, doi: 10.1016/j.tins.2016.09.003 (2016).
3. Luk, K. C. *et al.* Pathological  $\alpha$ -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice. *Science* **338**, 949–953, doi: 10.1126/science.1227157 (2012).
4. Rey, N. L., Petit, G. H., Bousset, L., Melki, R. & Brundin, P. Transfer of human  $\alpha$ -synuclein

478 from the olfactory bulb to interconnected brain regions in mice. *Acta Neuropathol. (Berl.)* **126**,  
479 555–573, doi: 10.1007/s00401-013-1160-3 (2013).

480 5. Guo, J. L. *et al.* Distinct  $\alpha$ -Synuclein Strains Differentially Promote Tau Inclusions in  
481 Neurons. *Cell* **154**, 103–117, doi: 10.1016/j.cell.2013.05.057, 10.1093/brain/awt037 (2013).

482 6. Masuda-Suzukake, M. *et al.* Prion-like spreading of pathological  $\alpha$ -synuclein in brain. *Brain*  
483 **136**, 1128–1138, doi: 10.1093/brain/awt037 (2013).

484 7. Volpicelli-Daley, L. A. *et al.* Exogenous  $\alpha$ -Synuclein Fibrils Induce Lewy Body Pathology  
485 Leading to Synaptic Dysfunction and Neuron Death. *Neuron* **72**, 57–71, doi:  
486 10.1016/j.neuron.2011.08.033 (2011).

487 8. Peelaerts, W. *et al.*  $\alpha$ -Synuclein strains cause distinct synucleinopathies after local and  
488 systemic administration. *Nature* **522**, 340–344, doi: 10.1038/nature14547 (2015).

489 9. Lázaro, D. F., Pavlou, M. A. S. & Outeiro, T. F. Cellular models as tools for the study of the  
490 role of alpha-synuclein in Parkinson's disease. *Exp. Neurol.* **298**, 162–171, doi:  
491 10.1016/j.expneurol.2017.05.007 (2017).

492 10. Lee, H.-J., Patel, S. & Lee, S.-J. Intravesicular localization and exocytosis of alpha-synuclein  
493 and its aggregates. *J. Neurosci. Off. J. Soc. Neurosci.* **25**, 6016–6024, doi:  
494 10.1523/JNEUROSCI.0692-05.2005 (2005).

495 11. Luk, K. C. *et al.* Intracerebral inoculation of pathological  $\alpha$ -synuclein initiates a rapidly  
496 progressive neurodegenerative  $\alpha$ -synucleinopathy in mice. *J. Exp. Med.* **209**, 975–986, doi:  
497 10.1084/jem.20112457 (2012).

498 12. Mougenot, A.-L. *et al.* Prion-like acceleration of a synucleinopathy in a transgenic mouse  
499 model. *Neurobiol. Aging* **33**, 2225–2228, doi: 10.1016/j.neurobiolaging.2011.06.022 (2012).

500 13. Recasens, A. *et al.* Lewy body extracts from Parkinson disease brains trigger  $\alpha$ -synuclein  
501 pathology and neurodegeneration in mice and monkeys: LB-Induced Pathology. *Ann. Neurol.* **75**,  
502 351–362, doi: 10.1002/ana.24066 (2014).

503 14. Woerman, A. L. *et al.* Propagation of prions causing synucleinopathies in cultured cells.  
504 *Proc. Natl. Acad. Sci.* **112**, E4949–E4958, doi: 10.1073/pnas.1513426112 (2015).

505 15. Luk, K. C. *et al.* Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like  
506 intracellular inclusions in cultured cells. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 20051–20056, doi:  
507 10.1084/jem.20112457 (2009).

508 16. Sacino, A. N. *et al.* Intramuscular injection of  $\alpha$ -synuclein induces CNS  $\alpha$ -synuclein  
509 pathology and a rapid-onset motor phenotype in transgenic mice. *Proc. Natl. Acad. Sci. U. S. A.*  
510 **111**, 10732–10737, doi: 10.1073/pnas.1321785111 (2014).

511 17. Lee, M. K. *et al.* Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-  
512 53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in  
513 transgenic mice. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 8968–8973, doi: 10.1073/pnas.132197599  
514 (2002).

515 18. Colla, E. *et al.* Endoplasmic Reticulum Stress Is Important for the Manifestations of -  
516 Synucleinopathy In Vivo. *J. Neurosci.* **32**, 3306–3320, doi: 10.1523/JNEUROSCI.5367-11.2012  
517 (2012).

518 19. Fujiwara, H. *et al.* alpha-Synuclein is phosphorylated in synucleinopathy lesions. *Nat. Cell*  
519 *Biol.* **4**, 160–164, doi: 10.1038/ncb748 (2002).

520 20. Colla, E. *et al.* Toxic properties of microsome-associated alpha-synuclein species in mouse  
521 primary neurons. *Neurobiol. Dis.* **111**, 36–47, doi: 10.1016/j.nbd.2017.12.004 (2018).

21. Colla, E. *et al.* Accumulation of Toxic  $\alpha$ -Synuclein Oligomer within Endoplasmic Reticulum Occurs in  $\alpha$ -Synucleinopathy In Vivo. *J. Neurosci.* **32**, 3301–3305, doi: 10.1523/JNEUROSCI.5368-11.2012 (2012).
22. Volpicelli-Daley, L. A., Luk, K. C. & Lee, V. M.-Y. Addition of exogenous  $\alpha$ -synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous  $\alpha$ -synuclein to Lewy body and Lewy neurite-like aggregates. *Nat. Protoc.* **9**, 2135–2146, doi: 10.1038/nprot.2014.143 (2014).
23. Li, W. *et al.* Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 2162–2167, doi: 10.1073/pnas.0406976102 (2005).
24. Luk, K. C. *et al.* Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity. *Cell Rep.* **16**, 3373–3387, doi: 10.1016/j.celrep.2016.08.053 (2016).
25. Volpicelli-Daley, L. A., Kirik, D., Stoyka, L. E., Standaert, D. G. & Harms, A. S. How can rAAV- $\alpha$ -synuclein and the fibril  $\alpha$ -synuclein models advance our understanding of Parkinson's disease? *J. Neurochem.* **139**, 131–155, doi: 10.1111/jnc.13627 (2016).



# Figure 1






Figure 2




Figure 3





Figure 4

A



B




Figure 5





Figure 6



Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Sucrose	Sigma-Aldrich	84097-1KG	
Hepes	Sigma-Aldrich	H0887-100ML	1M pH=7-7.6
EDTA	Sigma-Aldrich	0390-100ml	pH=8 0.5M
MgCl <sub>2</sub>	Sigma-Aldrich	M8266-100G	
NaCO <sub>3</sub>	Sigma-Aldrich	S7795-500G	
NAHCO <sub>3</sub>	Sigma-Aldrich	S5761-500G	
Methanol	Sigma-Aldrich	322415-6X1L	
KCl	Sigma-Aldrich	P9541-500G	
cOmplete Mini	Roche	11836170001	protease inhibitor
PhosStop	Roche	4906837001	phosphatase inhibitor
BCA Protein Assay Kit	Euroclone	EMPO14500	
Criterion TGX 4-20% Stain Free, 18 wells	Biorad	5678094	
Supported Nitrocellulose membrane	Biorad	1620097	0.2 µm
Blotting-Grade Blocker	Biorad	1706404	Non-fat dry milk
SuperSignal West Pico Chemiluminescent Substrate	Termo Fisher Scientific	34077	
Nitric acid	Sigma-Aldrich	1004411000	65%
Glass Coverslips	Termo Fisher Scientific	1014355118NR1	18 mm ☉
Poly-D-Lysine	Sigma-Aldrich	P7280	
Hank's Balanced Salt Solution	Termo Fisher Scientific	14170-500 mL	
Penicillin/Streptomycin	Termo Fisher Scientific	15140122	10,000 U/mL, 100 mL
Dulbecco's Modified Eagle's Medium	Termo Fisher Scientific	D5796-500 mL	
Trypsin-EDTA	Termo Fisher Scientific	15400054	0.50%
B27 Supplement	Termo Fisher Scientific	17504044	50X
Glutamax	Termo Fisher Scientific	35050-038	100x
DNAse	Sigma-Aldrich	D5025	
Fetal bovine serum	Euroclone	EC50182L	
Glutamate	Sigma-Aldrich	1446600-1G	
Gentamicin	Termo Fisher Scientific	15710	10 mg/ml
Neurobasal Medium	Termo Fisher Scientific	10888-022	
Cytosine arabinoside (AraC)	Sigma-Aldrich	C3350000	
VECTASHIELD antifade mounting medium	Vector Laboratories	H-1000	
DAPI	Termo Fisher Scientific	62247	
90 Ti rotor	Beckman	N/A	Ultracentrifuge rotor
Optima L-90K Ultracentrifuge	Beckman	N/A	
Syn-1 antibody, clone 42	BD Biosciences	610786	anti-mouse WB: 1:5000
Syn303 antibody	BioLegend	824301	anti-mouse IF: 1:1000
Tau antibody	Synaptic Systems	314 002	anti-rabbit IF: 1:10,000
pser129-αS antibody	A gift from Fujiwara et al, reference 19		anti-rabbit WB: 1:5000
pser129-αS antibody	Abcam	ab51253	anti-rabbit IF: 1:1000
Mouse αS (D37A6) XP	Cell Signaling	4179	anti-rabbit IF 1:200
Alexa fluor 555-conjugated anti-rabbit antibody	Termo Fisher Scientific	A27039	
Alexa fluor 488-conjugated anti-mouse antibody	Termo Fisher Scientific	A-11029	
Microson XL-2000	Misonix		Sonicator
Ultra Bottles (Oakridge Bottles), PCB, 16x76mm, Assembly, Noryl	Science Service EU	S4484	Ultracentrifuge tubes
AXIO Observer Inverted Light Microscope	Zeiss	N/A	
TCS SP2 laser scanning confocal microscope	Leica	N/A	
Inverted epi-fluorescence microscope	Nikon	N/A	
Triton x-100	Sigma-Aldrich	X100-500ML	Nonionic surfactant



1 Alewife Center #200  
 Cambridge, MA 02140  
 tel. 617.945.9051  
[www.jove.com](http://www.jove.com)

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: Exogenous administration of microsomes-associated alpha-synuclein aggregates to primary neurons as a powerful cell model of fibrils formation.

Author(s): Panattoni Giulia, Colla Emanuela

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☐ Standard Access ☒ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJove Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.



## ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have



## ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

### CORRESPONDING AUTHOR:

Name:

Emanuela Colla

Department:

Bio@SNS

Institution:

Scuola Normale Superiore

Article Title:

Exogenous administration of microsomes-associated alpha-synuclein aggregates to primary neurons as a powerful cell model of fibrils formation.

Signature:



Date:

02/22/2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email [submissions@jove.com](mailto:submissions@jove.com) or call +1.617.945.9051

## **Response to Editor's comments.**

**1) We cannot have long paragraphs of text in the protocol section, so this is moved to the introduction. Please check. Please add an opening sentence to the paragraph.**

We modified the opening sentence to include this paragraph in the introduction section (Line 91).

**2) Please remove the commercial language and use generic term instead.**

We changed Neurobasal medium with the generic term plating medium (Line 223, 230, 233).

**3) Needs citation. Also, this note is not very important can be removed. The second sentence can be moved as a note after first wash step.**

We removed this note and moved the second sentence after the first wash step (Line 268).

**4) Nonionic surfactant to make it generic.**

We removed Tx-100 and replaced it with nonionic surfactant (Line 269).

**5) Mention antibodies against which proteins were used as a note under this step.**

We added the antibodies used in the immunofluorescence assay (Line 276).

**6) Please remove the commercial language and use generic term instead.**

We removed the commercial names of all the microscopes (Line 335, 360, 375, 383) and added them to the Material file.

**7) Please convert minutes to min throughout the figure. And hour to h.**

We modified figure 2 accordingly.

**8) Please explain what does ntg, PreS and sick stand for in the figure.**

We added extra details in figure 3 legend, explaining better what ntg, PreS and sick stand.

**10) Please mark a, b, c out the figures and capitalize to make it same throughout all figures.**

We modified figure 5 accordingly.

**11) 1 and 2 microgram of what?**

We apologize for the mistake. We added 1, 2  $\mu$ g of microsomes-associated  $\alpha$ S aggregates (Line 381) and clarify what buffer means.

## EDITORIAL POLICY for Neurobiology of DISEASE

**How can I get permission to reproduce or re-use Elsevier content?** Last updated on 12/02/2018 01:41 PM

As a general rule, permission should be sought from the rightsholder to reproduce any substantial part of a copyrighted work. This includes any text, illustrations, charts, tables, photographs, or other material from previously published sources.

### Obtaining permission to use content on ScienceDirect

If the content you wish to re-use is on [ScienceDirect](#), you can request permission using the Copyright Clearance Center's Rightslink® service. Rightslink is available on each journal article or book chapter page by clicking 'Get rights and content' button located under the title and authors' names, to the right of the DOI. For more information, please [click here](#).

Certain requests may require further review by Elsevier's Global Rights Department before permission can be granted. If this occurs, you'll receive an email notification from Rightslink to accept or decline the terms of the permissions license and (if applicable) a permission fee.

**Please note:** when you create an account with Rightslink you will be asked to provide your credit card information. This does not necessarily mean that your request will be subject to a permissions fee; it is part of the registration process only. You can determine whether your request is subject to a fee by clicking 'Quick Price' after you have made your selection on how you wish to use the material.

Colla, E. *et al.*

Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons. *Neurobiol. Dis.* **111**, 36–47, doi: 10.1016/j.nbd.2017.12.004 (2018)  
<https://www.sciencedirect.com/science/article/pii/S0969996117302826>

Open access

Under a Creative Commons [license](#) (Copyright Clearance Center's Rightslink® service)

### Creative Commons Attribution License (CC BY)

This article is available under the terms of the Creative Commons Attribution License (CC BY). You may copy and distribute the article, create extracts, abstracts and new works from the article, alter and revise the article, text or data mine the article and otherwise reuse the article commercially (including reuse and/or resale of the article) without permission from Elsevier. You must give appropriate credit to the original work, together with a link to the formal publication through the relevant DOI and a link to the Creative Commons user license above. You must indicate if any changes are made but not in any way that suggests the licensor endorses you or your use of the work.

Permission is not required for this type of reuse.

## EDITORIAL POLICY

### ***The Journal of Neuroscience* Permissions Policy**

August 2017

Authors grant *The Journal of Neuroscience* a license to publish their work. Copyright remains with the author. The License to Publish grants the Society for Neuroscience a 6-month period to exclusively publish the article. After 6 months, the work becomes available to the public to copy, distribute, or display under the terms of the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>). These agreements allow data and text mining, use of figures in presentations, and posting the article online, as long as the original article is attributed.

**Material published in 2014 and earlier** is released under a different license, the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License (<http://creativecommons.org/licenses/by-nc-sa/3.0/>). Under this license, reuse of material in a new work published by a nonprofit publisher does not carry a fee. Republishing content with a for-profit publisher does carry a fee, including for original authors. Follow the "Request Permissions" link in the sidebar to the right of any full-text article, which brings you to the Copyright Clearance Center to complete your request.

Authors do not need to contact the journal to obtain rights for any nonprofit reuse of their material as long as they provide proper attribution to the place of original publication and, for the first six months after publication, refrain from making the work publicly available.

Authors are allowed to post a copy of their article in an institutional repository or on their website following the first six months after publication, as long as appropriate credit is provided to the work published in *JNeurosci*.

Please email a detailed request to [jnpermissions@sfn.org](mailto:jnpermissions@sfn.org) for the following:

☐ \_If you are not an original author and are requesting permission to reproduce material with a nonprofit publisher

☐ \_If you are a student and are requesting permission to reproduce material in your thesis or dissertation. There is no fee to reproduce material in a thesis or dissertation.

Contact the *JNeurosci* Central Office at [jnpermissions@sfn.org](mailto:jnpermissions@sfn.org) with any questions.

We requested the permission for republishing through Copyright Clearance Center. Attached is the receipt for the fee payment. Request has been granted.



**Note:** Copyright.com supplies permissions but not the copyrighted content itself.

1 PAYMENT      2 REVIEW      3 CONFIRMATION

Step 3: Order Confirmation

**Thank you for your order!** A confirmation for your order will be sent to your account email address. If you have questions about your order, you can call us 24 hrs/day, M-F at +1.855.239.3415 Toll Free, or write to us at [info@copyright.com](mailto:info@copyright.com). This is not an invoice.

**Confirmation Number: 11700516**  
**Order Date: 02/22/2018**

If you paid by credit card, your order will be finalized and your card will be charged within 24 hours. If you choose to be invoiced, you can change or cancel your order until the invoice is generated.

Payment Information

Emanuela Colla  
[emanuela.colla@sns.it](mailto:emanuela.colla@sns.it)  
+39 3299865040  
Payment Method: CC ending in 1000

Order Details

The journal of neuroscience : the official journal of the Society for Neuroscience

<b>Order detail ID:</b>	71029321	<b>Permission Status:</b>	✔ Granted
<b>Order License Id:</b>	4294080040123	<b>Permission type:</b>	Republish or display content
<b>ISSN:</b>	1529-2401	<b>Type of use:</b>	Republish in a journal/magazine
<b>Publication Type:</b>	e-Journal		
<b>Volume:</b>		<b>Requestor type</b>	Publisher, for-profit
<b>Issue:</b>			
<b>Start page:</b>		<b>Format</b>	Electronic
<b>Publisher:</b>	SOCIETY FOR NEUROSCIENCE	<b>Portion</b>	image/photo
<b>Author/Editor:</b>	Society for Neuroscience	<b>Number of images/photos requested</b>	1
		<b>The requesting person/organization</b>	Emanuela Colla/Scuola Normale Superiore
		<b>Title or numeric reference of the portion(s)</b>	Figure 4, Panel F
		<b>Title of the article or chapter the portion is from</b>	Endoplasmic Reticulum Stress Is Important for the Manifestations of α-Synucleinopathy In Vivo
		<b>Editor of portion(s)</b>	N/A
		<b>Author of portion(s)</b>	Emanuela Colla, Philippe Coune, Ying Liu, Olga Pletnikova, Juan C

**Note:** This item will be invoiced or charged separately through CCC's **RightsLink** service. [More info](#) **\$ 93.50**

<hr/>		
<b>Total order items: 1</b>	<b>This is not an invoice.</b>	<b>Order Total: 75.82 EUR (93.50 USD)</b>

**Confirmation Number: 11700516****Special Rightsholder Terms & Conditions**

The following terms & conditions apply to the specific publication under which they are listed

**The journal of neuroscience : the official journal of the Society for Neuroscience****Permission type:** Republish or display content**Type of use:** Republish in a journal/magazine**TERMS AND CONDITIONS****The following terms are individual to this publisher:**

None

**Other Terms and Conditions:****STANDARD TERMS AND CONDITIONS**

1. Description of Service; Defined Terms. This Republication License enables the User to obtain licenses for republication of one or more copyrighted works as described in detail on the relevant Order Confirmation (the "Work(s)"). Copyright Clearance Center, Inc. ("CCC") grants licenses through the Service on behalf of the rightsholder identified on the Order Confirmation (the "Rightsholder"). "Republication", as used herein, generally means the inclusion of a Work, in whole or in part, in a new work or works, also as described on the Order Confirmation. "User", as used herein, means the person or entity making such republication.

2. The terms set forth in the relevant Order Confirmation, and any terms set by the Rightsholder with respect to a particular Work, govern the terms of use of Works in connection with the Service. By using the Service, the person transacting for a republication license on behalf of the User represents and warrants that he/she/it (a) has been duly authorized by the User to accept, and hereby does accept, all such terms and conditions on behalf of User, and (b) shall inform User of all such terms and conditions. In the event such person is a "freelancer" or other third party independent of User and CCC, such party shall be deemed jointly a "User" for purposes of these terms and conditions. In any event, User shall be deemed to have accepted and agreed to all such terms and conditions if User republishes the Work in any fashion.

**3. Scope of License; Limitations and Obligations.**

3.1 All Works and all rights therein, including copyright rights, remain the sole and exclusive property of the Rightsholder. The license created by the exchange of an Order Confirmation (and/or any invoice) and payment by User of the full amount set forth on that document includes only those rights expressly set forth in the Order Confirmation and in these terms and conditions, and conveys no other rights in the Work(s) to User. All rights not expressly granted are hereby reserved.

3.2 General Payment Terms: You may pay by credit card or through an account with us payable at the end of the month. If you and we agree that you may establish a standing account with CCC, then the following terms apply: Remit Payment to: Copyright Clearance Center, 29118 Network Place, Chicago, IL 60673-1291. Payments Due: Invoices are payable upon their delivery to you (or upon our notice to you that they are available to you for downloading). After 30 days, outstanding amounts will be subject to a service charge of 1-1/2% per month or, if less, the maximum rate allowed by applicable law. Unless otherwise specifically set forth in the Order Confirmation or in a separate written agreement signed by CCC, invoices are due and payable on "net 30" terms. While User may exercise the rights licensed immediately upon issuance of the Order Confirmation, the license is automatically revoked and is null and void, as if it had never been issued, if complete payment for the license is not received on a timely basis either from User directly or through a payment agent, such as a credit card company.

3.3 Unless otherwise provided in the Order Confirmation, any grant of rights to User (i) is "one-time" (including the editions and product family specified in the license), (ii) is non-exclusive and non-transferable and (iii) is subject to any and all limitations and restrictions (such as, but not limited to, limitations on duration of use or circulation) included in the Order Confirmation or invoice and/or in these terms and conditions. Upon completion of the licensed use, User shall either secure a new permission for further use of the Work(s) or immediately cease any new use of the Work(s) and shall render inaccessible (such as by deleting or by removing or severing links or other locators) any further copies of the Work (except for copies printed on paper in accordance with this license and still in User's stock at the end of such period).

3.4 In the event that the material for which a republication license is sought includes third party materials (such as photographs, illustrations, graphs, inserts and similar materials) which are identified in such material as having been used by permission, User is responsible for identifying, and seeking separate licenses (under this Service or otherwise) for, any of such third party materials; without a separate license, such third party materials may not be used.

3.5 Use of proper copyright notice for a Work is required as a condition of any license granted under the Service. Unless otherwise provided in the Order Confirmation, a proper copyright notice will read substantially as follows: "Republished with permission of [Rightsholder's name], from [Work's title, author, volume, edition number and year of copyright]; permission conveyed through Copyright Clearance Center, Inc. " Such notice must be provided in a reasonably legible font size and must be placed either immediately adjacent to the Work as used (for example, as part of a by-line or footnote but not as a separate electronic link) or in the place where substantially all other credits or notices for the new

work containing the republished Work are located. Failure to include the required notice results in loss to the Rightsholder and CCC, and the User shall be liable to pay liquidated damages for each such failure equal to twice the use fee specified in the Order Confirmation, in addition to the use fee itself and any other fees and charges specified.

3.6 User may only make alterations to the Work if and as expressly set forth in the Order Confirmation. No Work may be used in any way that is defamatory, violates the rights of third parties (including such third parties' rights of copyright, privacy, publicity, or other tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In addition, User may not conjoin a Work with any other material that may result in damage to the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any infringement of any rights in a Work and to cooperate with any reasonable request of CCC or the Rightsholder in connection therewith.

4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and their respective employees and directors, against all claims, liability, damages, costs and expenses, including legal fees and expenses, arising out of any use of a Work beyond the scope of the rights granted herein, or any use of a Work which has been altered in any unauthorized way by User, including claims of defamation or infringement of rights of copyright, publicity, privacy or other tangible or intangible property.

5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK, EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their respective employees and directors) shall not exceed the total amount actually paid by User for this license. User assumes full liability for the actions and omissions of its principals, employees, agents, affiliates, successors and assigns.

6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED "AS IS". CCC HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS, GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.

7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User of a Work beyond the scope of the license set forth in the Order Confirmation and/or these terms and conditions, shall be a material breach of the license created by the Order Confirmation and these terms and conditions. Any breach not cured within 30 days of written notice thereof shall result in immediate termination of such license without further notice. Any unauthorized (but licensable) use of a Work that is terminated immediately upon notice thereof may be liquidated by payment of the Rightsholder's ordinary license price therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any reason (including, for example, because materials containing the Work cannot reasonably be recalled) will be subject to all remedies available at law or in equity, but in no event to a payment of less than three times the Rightsholder's ordinary license price for the most closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses incurred in collecting such payment.

#### **8. Miscellaneous.**

8.1 User acknowledges that CCC may, from time to time, make changes or additions to the Service or to these terms and conditions, and CCC reserves the right to send notice to the User by electronic mail or otherwise for the purposes of notifying User of such changes or additions; provided that any such changes or additions shall not apply to permissions already secured and paid for.

8.2 Use of User-related information collected through the Service is governed by CCC's privacy policy, available online here: <http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html>.

8.3 The licensing transaction described in the Order Confirmation is personal to User. Therefore, User may not assign or transfer to any other person (whether a natural person or an organization of any kind) the license created by the Order Confirmation and these terms and conditions or any rights granted hereunder; provided, however, that User may assign such license in its entirety on written notice to CCC in the event of a transfer of all or substantially all of User's rights in the new material which includes the Work(s) licensed under this Service.

8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed by the parties. The Rightsholder and CCC hereby object to any terms contained in any writing prepared by the User or its principals, employees, agents or affiliates and purporting to govern or otherwise relate to the licensing transaction described in the Order Confirmation, which terms are in any way inconsistent with any terms set forth in the Order Confirmation and/or in these terms and conditions or CCC's standard operating procedures, whether such writing is prepared prior to, simultaneously with or subsequent to the Order Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a separate instrument.

8.5 The licensing transaction described in the Order Confirmation document shall be governed by and construed under the law of the State of New York, USA, without regard to the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding arising out of, in connection with, or related to such licensing transaction shall be brought, at CCC's sole discretion, in any federal or state court located in the County of New York, State of New York, USA, or in any federal or state court whose geographical jurisdiction covers the location of the Rightsholder set forth in the Order Confirmation. The parties expressly submit to the personal jurisdiction and venue of each such federal or state court. If you have any comments or questions about the Service or Copyright Clearance Center, please contact us at 978-750-8400 or send an e-mail to [info@copyright.com](mailto:info@copyright.com).



Close

**Confirmation Number: 11700516**

**Citation Information**

**Order Detail ID:** 71029321

**The journal of neuroscience : the official journal of the Society for Neuroscience by Society for Neuroscience  
Reproduced with permission of SOCIETY FOR NEUROSCIENCE in the format Republish in a journal/magazine via  
Copyright Clearance Center.**

Close